The Director of Murdoch University’s Institute for Immunology & Infectious Diseases has been named one of 11 finalists for the 2012 GlaxoSmithKline Award for Research Excellence (ARE).
Professor Simon Mallal has been nominated for his research into genetic testing to prevent drug hypersensitivity. This work has led to significant advancements in both international HIV treatment guidelines and understanding drug toxicity.
Professor Mallal said the nomination was an honour, especially as the jury consisted of previous ARE winners and leading Australian researchers.
“It is always rewarding to be recognised by one’s peers, and with its long history, the GlaxoSmithKline Award for Research Excellence would be a feather in any researcher’s cap,” Professor Mallal said.
“I look forward to the ceremony and extend my congratulations to all of my very worthy co-nominees. Their work is making a vital difference to health in Australia and the world.”
As well as undertaking research at Murdoch University, Professor Mallal is a Consultant Clinical Immunologist at the Department of Clinical Immunology, Royal Perth Hospital, where he manages the care of patients with HIV, allergic and autoimmune diseases and provides immunopathology supervision of the routine laboratories.
Now in its 32nd year, the ARE will be announced on September 11, 2012 at the Melbourne Museum. The award winner will receive an $80,000 research grant.